research Anaphylactic shock associated with finasteride and terazosin
Combining finasteride and terazosin can cause severe allergic reactions.
Search
for
Sort by
Research
690-720 / 1000+ results
research Alternative synthesis of the anti-baldness compound RU58841
A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
research The Comparative Potency of Hydrocortisone Analogs in Suppressing Growth of Hair in the Rat121From the Departments of Dermatology and Syphilology and of Anatomy, University of Michigan Medical School, Ann Arbor, Michigan.2Supported in part by research grants from the National Institutes of Health, United States Public Health Service (A-131 (C5)), the University of Michigan Memorial-Phoenix Project #145 and The Upjohn Company.
research Decision letter for "Repeated finasteride administration promotes synaptic plasticity and produces antidepressant‐ and anxiolytic‐like effects in female rats"
research Decision letter for "Repeated finasteride administration promotes synaptic plasticity and produces antidepressant‐ and anxiolytic‐like effects in female rats"
research Treatment of corticosteroid-refractory alopecia totalis with oral tacrolimus
Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
research Effect of Citrullus coclocynthis Schrad on hair growth activity of albino rats
Citrullus colocynthis extracts may promote hair growth as effectively as minoxidil.
research A Case of Rhupus with Rowell Syndrome
A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.
![Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1](/images/research/ff6e6cbe-cb9c-4d11-87ef-671d28ffd4fa/small/15506.jpg)
research Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1
Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research A single center, pilot, double-blinded, randomized, comparative, prospective clinical study to evaluate improvements in the structure and function of facial skin with tazarotene 0.1% cream alone and in combination with GliSODin® Skin Nutrients Advanced A
Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
research Dermatological drugs, topical agents, and cosmetics
The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research 198 Dutasteride for men with androgenic alopecia unresponsive to finasteride
research Impact of dutasteride on spermatogenesis and oxidative status in rats.
Dutasteride did not change rat spermatogenesis or oxidative stress but needs more research.
research Adverse effect profile with low-dose methotrexate therapy in patients suffering with rheumatic diseases
Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
research Hypersensitivity to intravenous ondansetron: a case report
Ondansetron can cause serious allergic reactions, so use it carefully.
research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
research Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice
Letrozole reduces seizures but not brain damage in mice.